REMUS Peer Comparison

NSE: REMUS

₹925.00

₹14.85 (1.63%)

As on 28-Aug-2026IST

Market cap

₹1,090 Cr

Revenue (TTM)

₹620 Cr

P/E Ratio

29.5

P/B Ratio

3.1

Div. Yield

0.1 %

Edit

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	1,090	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	620	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	38.42	414.00	288.22	-371.81	387.35
Net Margin (%)	6.14	11.23	14.79	-3.93	26.01
RoE (%)	18.58	8.38	29.77	-3.85	25.18
Price to Earnings	29.47	78.49	103.71	--	69.57
Price-To-Book	3.11	6.38	22.27	3.64	15.55

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	620.36	3,012.00	1,284.27	9,151.18	1,006.88
Total Income	625.34	3,074.00	1,296.22	9,312.95	1,023.80
Total Expenditure	574.67	2,619.00	1,028.33	7,733.31	774.80
EBITDA	45.69	393.00	255.95	1,417.87	232.07
Depreciation	1.87	217.00	36.59	816.34	26.62
EBIT	43.82	176.00	219.36	601.53	205.45
Interest	1.46	254.00	36.78	421.59	6.22
Other Income	4.98	62.00	11.95	161.77	16.93
Exceptional Items	--	--	--	--	--
Profit before Tax	47.34	-16.00	194.52	414.64	216.16
Provision for Tax	8.92	41.00	60.16	323.51	55.75
Profit after Tax	38.42	-57.00	134.36	91.13	160.42

Liabilities (₹ Cr)

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	255.86	4,353.00	540.98	8,125.47	1,309.63
Minority Interest	26.69	304.00	0.00	--	10.45
Non-Current Liabilities	28.56	887.00	122.65	3,392.72	26.93
Current Liabilities	121.53	2,042.00	786.03	3,850.56	202.25
Total Liabilities	432.64	8,100.00	1,451.43	15,513.53	1,549.26

Assets (₹ Cr)

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	211.27	5,017.00	386.29	9,487.47	757.63
Current Assets	221.37	2,465.00	1,063.37	5,881.28	791.64
Total Assets	432.64	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	20.81	1,859.00	393.17	4,720.27	8.18
Net Current Assets	99.84	423.00	277.34	2,030.72	589.39
Contingent Liabilities	--	770.26	12.25	99.76	15.38

Cashflow (₹ Cr)

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	6.98	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-10.55	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	6.07	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	2.50	-396.00	54.56	-25.99	155.52

Ratios

Profitability Ratios

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	21.89	4.07	26.97	6.61	20.14
ROE (%)	18.58	-1.48	30.68	1.14	16.19
ROA (%)	10.03	-0.78	10.50	0.60	12.13
EBIT Margin (%)	8.17	15.11	20.86	17.26	24.73
Net Margin (%)	6.14	-1.85	10.37	0.98	15.67
Cash Profit Margin (%)	6.49	4.14	7.13	8.54	18.58

Growth Ratios

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	191.33	7.65	50.40	11.99	40.34
EBIT Growth (%)	59.39	272.95	54.77	15.16	83.12
Net Profit Growth (%)	58.24	87.92	47.63	411.39	229.35
EPS Growth (%)	41.36	90.35	45.69	410.84	67.16
Book Value Growth (%)	62.26	29.77	42.49	2.28	94.96

Valuation Ratios

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	22.68	0.00	0.00	326.26	62.97
Price / Book Value	5.15	5.31	0.00	3.69	15.26
Dividend Yield (%)	0.07	0.00	--	0.06	0.06
EV/EBITDA	26.28	54.36	1.09	21.49	79.31
Market Cap (₹ Cr)	1,318.76	23,064.69	0.00	29,731.27	19,988.69

Solvency Ratios

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.08	0.43	0.76	0.59	0.01
Short term debt to equity ratio	0.07	0.11	0.54	0.12	0.01
Current Ratio	1.82	1.21	1.35	1.53	3.91
Quick Ratio	1.40	0.85	0.69	0.93	3.02
Interest Coverage	33.42	0.94	6.29	1.98	35.76

Operating Efficiency Ratios

	REMUS	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	17.41	21.95	25.21	25.67	28.85
Asset Turnover	1.62	0.53	1.87	0.70	0.76
Receivable days	65.70	60.36	47.59	77.05	90.06
Inventory Days	27.85	64.42	62.58	77.13	61.02
Payable days	56.51	218.94	228.78	173.49	96.06
Cash Conversion Cycle	37.04	-94.15	-118.62	-19.30	55.02